SEC Company Response from Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654) (ORKA) — Jul 16, 2015
Oruka Therapeutics, Inc. (ORKA) (CIK 0000907654)
Date: July 16, 2015 · CIK: 0000907654 · Accession: 0001193125-15-254859
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-205533
Letter
Re: ARCA biopharma, Inc.
July 16, 2015
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-3
Filed: July 7, 2015
File No. 333-205533
Ladies and Gentlemen:
ARCA biopharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced filing to become effective at 4:00 p.m. Eastern Time on Monday, July 20, 2015, or as soon thereafter as is practicable.
The Company hereby acknowledges that:
•
should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
•
the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
•
the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Sincerely,
ARCA BIOPHARMA, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP July 16, 2015 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: ARCA biopharma, Inc. Registration Statement on Form S-3 Filed: July 7, 2015 File No. 333-205533 Ladies and Gentlemen: ARCA biopharma, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced filing to become effective at 4:00 p.m. Eastern Time on Monday, July 20, 2015, or as soon thereafter as is practicable. The Company hereby acknowledges that: • should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; • the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and • the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Sincerely, ARCA BIOPHARMA, INC. By: /s/ Brian L. Selby Brian L. Selby Vice President, Finance cc: Jeffrey P. Riedler, Assistant Director, SEC Christina De Rosa, Esq., SEC Brent D. Fassett, Esq., Cooley LLP